Acer Therapeutics Valuation
| ACERDelisted Stock | USD 0.84 0.02 2.33% |
Today, the firm appears to be overvalued. Acer Therapeutics shows a prevailing Real Value of $0.73 per share. The current price of the firm is $0.84. Our model approximates the value of Acer Therapeutics from analyzing the firm fundamentals such as current valuation of 52.01 M, and Return On Equity of -4.73 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Acer Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of Acer Therapeutics is based on 3 months time horizon. Increasing Acer Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Acer stock is determined by what a typical buyer is willing to pay for full or partial control of Acer Therapeutics. Since Acer Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Acer Stock. However, Acer Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.84 | Real 0.73 | Hype 0.84 | Naive 0.83 |
The intrinsic value of Acer Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Acer Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Acer Therapeutics helps investors to forecast how Acer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Acer Therapeutics more accurately as focusing exclusively on Acer Therapeutics' fundamentals will not take into account other important factors: Acer Therapeutics Total Value Analysis
Acer Therapeutics is presently forecasted to have valuation of 52.01 M with market capitalization of 22.02 M, debt of 11.86 M, and cash on hands of 14.47 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Acer Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
52.01 M | 22.02 M | 11.86 M | 14.47 M |
Acer Therapeutics Asset Utilization
One of the ways to look at asset utilization of Acer is to check how much profit was generated for every dollar of assets it reports. Acer Therapeutics shows a negative utilization of assets of -0.65 percent, losing $0.006527 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Acer Therapeutics shows how unproductive it operates for each dollar spent on its assets.Acer Therapeutics Ownership Allocation
Acer Therapeutics holds a total of 24.46 Million outstanding shares. Acer Therapeutics shows significant amount of outstanding shares owned by insiders and institutional investors . Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Acer Therapeutics Profitability Analysis
Net Loss for the year was (26.24 M) with profit before overhead, payroll, taxes, and interest of 1.26 M.About Acer Therapeutics Valuation
The delisted stock valuation mechanism determines Acer Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Acer Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Acer Therapeutics. We calculate exposure to Acer Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Acer Therapeutics's related companies.Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts. Acer Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 41 people.
Acer Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Acer Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 15.8 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Acer Stock
If you are still planning to invest in Acer Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acer Therapeutics' history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |